



Normative Letter 24-0206

February 6, 2024

To: Managed Care Organizations (MCOs), Pharmacy Benefit Manager (PBM), Pharmacies, Primary Medical Groups (PMG) and Vital Participant Providers

Re: Non-Risk Payment Arrangement for Hepatitis C, Synthroid and SMA Medications


The Puerto Rico Health Insurance Administration (PRHIA) is committed to guaranteeing access to high-cost therapies such as covered Spinal Muscular Atrophy (SMA), Hepatitis C, and other medications utilized to treat severe medical conditions for those beneficiaries in need. To ensure access, a Non-Risk Payment Arrangement has been implemented to meet the needs of this population without undermining the payments and costs of the MCOs' actuarial quoted premiums.

The products applicable to this agreement are the following:

1. Hepatitis C medications
 - a. Ribavirin 200 mg capsule
 - b. Eplclusa (sofosbuvir/velpatasvir 400-100 mg tablet)
 - c. Mavyret (glecaprevir-pibrentasvir 100-40 mg table)
 - d. Any other Hepatitis C drug approved by exception process by the MCOs.
2. Spinal Muscular Athropy (SMA) medications
 - a. Spinraza (nusinersen intrathecal solution 12mg/5 mL)
 - b. Zolgensma (onasemnogene abeparvovec -xioi kit)
 - c. Evrysdi (risdiplam oral solution 0.75 mg/ml)
3. Synthroid medications
 - a. **Clarification:** For Synthroid medications (brand only) the *Non-Risk Payment Arrangement will be applicable only for the difference in price between the generic and the brand product.* The contracted MCO will pay for the Synthroid generic price portion.

The PRHIA will continue bearing the risk 100 (%) percent and as a result these products will not be included in the MCOs' premiums. The MCOs are responsible to pay for the treatment when approved for the patients, upfront and ASES will reimburse these costs directly to the MCOs. The MCOs utilization shall be submitted to PRHIA on or before the 15th of each month and it will be reimbursed monthly by ASES directly to the MCOs. This revised payment process will be effective March 2024.

We thank you for your commitment and collaboration in this process.


Roxana K. Rosario Serrano, BHE, MS
Executive Director

Autorizado por la Oficina del Contralor Electoral OCE-SA-2024-00267